SPY303.53+4.45 1.49%
DIA255.77+5.52 2.21%
IXIC9,412.36+72.14 0.77%

RBC Capital Maintains Outperform on Oncolytics Biotech, Lowers Price Target to $6

RBC Capital maintains Oncolytics Biotech (NASDAQ:ONCY) with a Outperform and lowers the price target from $9 to $6.

Benzinga · 05/11/2020 12:17

RBC Capital maintains Oncolytics Biotech (NASDAQ:ONCY) with a Outperform and lowers the price target from $9 to $6.